Denosumab Experience in Metastatic Giant Cell Tumor of Bone: Case Series
PDF

Case report

Denosumab Experience in Metastatic Giant Cell Tumor of Bone: Case Series

Acta Haematol Oncol Turc 2014;47(3):67-69 DOI: 10.5505/aot.2014.38358
, , , , , ,
PDF
Permissions

Abstract

Giant cell tumor of bone (GCTB) is a rare benign primary tumor of the bone. Bisphosphonate therapy is curently used in GCTB because of its anti-osteoclastic effects. Denosumab is fully human monoclonal antibody that inhibit disease progression in metastatic GCTB. We summurized tree patients GCTB patients with lung metastasis. The patient were received between 12-18 months denosumab and remain without disease progression between 6-15 months after discontinuous of treatment. Due to the indolent nature of the tumor follow-up period may be short, however we thinks it is an important experience fort his condition

Keywords: denosumab, giant cell bone tumor, lung metastasis